Rexahn Pharmaceuticals (RNN) Announces Quarterly Earnings Results, Beats Estimates By $0.31 EPS

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) posted its quarterly earnings data on Monday. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.31, Fidelity Earnings reports.

Shares of RNN stock opened at $5.07 on Wednesday. Rexahn Pharmaceuticals has a 1 year low of $4.75 and a 1 year high of $28.56.

Several research firms recently commented on RNN. Zacks Investment Research downgraded Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. HC Wainwright set a $23.00 price objective on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, April 17th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $42.67.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer; and RX-5902 that is in Phase IIa clinical trials to treat patients with metastatic triple negative breast cancer.

Read More: What is a bull market?

Earnings History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.